An estimated 20,000 new cases of ovarian cancer will be diagnosed in 2022. While rare in women younger than 40 years old, around 50% of all ovarian cancers are found in women above the age of 60. Sadly, ovarian cancer is responsible for more deaths than any other gynecologic cancer. Intervention consists of surgical and medical modalities, while early detection plays a major role in successful treatment. This is why the search for novel medications, target therapy options and genetic risk factors remains a key area of development and importance in ovarian cancer research.
The Cureline group is a strong advocate of ovarian cancer research. Among its extensive human biospecimen repository are standard disassociated tumor cell (DTC) specimens from ovarian cancer, which are suitable for biomarker studies, drug sensitivity evaluation, and other functional assays. Cureline Molecular Services can provide support for protocol set-up and implementation on ovarian cancer research, as well as a wide variety of immune-oncology relevant cancers.
Contact us today via Cureline.com (insert QR code and link)
Statistics from the American Cancer Society, available from
